Experts discuss the potential of triple combination therapies for high-risk renal cell carcinoma (RCC) patients and the challenges posed by their toxicity profiles, emphasizing the need for compelling clinical trial data.
OncLive’s April Roundup of Key FDA Decisions in Oncology
FDA Approval Insights: Ponatinib in Ph+ ALL
Retrospective Data Show Metastasectomy Plus Nephrectomy Improves Survival in Non–ccRCC
CRC Experts Highlight AE Management and Prevention Strategies for TAS-102/Bevacizumab, Regorafenib, and Fruquintinib
The Surprising Connection Between Male Infertility and Family Cancer Risk
FDA Accepts BLA for Subcutaneous Nivolumab in Advanced or Metastatic Solid Tumors
Dr Liu Previews ASCO 2024 Lung Cancer Data
Dr Rajkumar Previews ASCO 2024 Data in Multiple Myeloma
Ribociclib Plus NSAI Maintains Manageable Safety Profile in HR+/HER2– Early Breast Cancer
Novel CDK4 Inhibitor Shows Activity and Safety in HR+/HER2– Metastatic Breast Cancer